Phase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With Letrozole
Phase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With Letrozole
Active, not recruiting · NCT05286437 · Registry updated 2026-07-14Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With Letrozole | Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer | Active, not recruiting | Phase 2 | 2026-07-14 | NCT05286437 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| MSD Pharma (Singapore) Pte Ltd | 1 |
| National Cancer Centre, Singapore | 44 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| National Cancer Centre Singapore | Singapore | Singapore | 15 |